Clinical Trials Search
Clinical Trial 17986
Cancer Type: Multiple
Interventions:CP-675,206 (tremelimumab); KW-0761 (Mogamulizumab); MEDI4736 (Durvalumab); Mogamulizumab; Not Applicable; tremelimumab
Study Type: Treatment
Phase of Study: Phase I
Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
The purpose of this study is to test the safety, tolerable adverse events (side effects) and determine the highest tolerable dose of a combination of three investigational study drugs, Mogamulizumab and MEDI4736 or Mogamulizumab and tremelimumab, in participants who have locally advanced or metastatic solid tumors.
To characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the highest protocol-defined dose in the absence of exceeding the MTD of the combinations of mogamulizumab+MEDI4736 and mogamulizumab+tremelimumab in subjects with locally advanced or metastatic disease.